Aurobindo receives FDA nod for generic Librax

Aurobindo has received the Food and Drug Administration’s nod for Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules 5 mg/2.5 mg, which is the generic of Bausch Health’s Librax.

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules are indicated to control emotional and somatic factors in gastrointestinal disorders; an d for adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.

[Read more: Aurobindo gets FDA nod for 3 generics]

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules have an estimated market value of $34 million for the 12 months ending July 2023, per IQVIA.

[Read more: Aurobindo receives FDA OK for generic Renagel]